Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV

• DOI: 10.1097/qai.0b013e31824a03b8
• Publication Date: 2012-01-20T10:08:06Z
• Authors: Kenneth H. Mayer; Matthew J. Mimiaga; Marcy Gelman; Chris Grasso
• Keywords: Raltegravir; Emtricitabine; Regimen; Ritonavir; Sexual transmission; Abacavir

Antiretroviral drugs have been recommended for postexposure prophylaxis (PEP) after high-risk sexual exposures more than a decade. Three drug regimens could offer the highest levels of protection, particularly if infectious source is taking medication, but intolerance has often led to suboptimal adherence. The current study evaluated novel 3-drug PEP regimen, consisting raltegravir, tenofovir DF, and emtricitabine. Of 100 participants enrolled in this at Boston community health center that had comprehensive program decade, 85 were evaluable 3 months none became HIV infected. Fifty seven percent those completed regimen as prescribed, 27% took their medicine daily, sometimes missed second daily dose Raltegravir. most common side effects reported included nausea or vomiting (27%), diarrhea (21%), headache (15%), fatigue (14%), abdominal symptoms (including pain, gas, bloating) (16%), myalgias arthralgias (8%), all which mild tended be self-limited, not resulting discontinuation. significantly less by historical controls, who used including zidovudine, lamivudine, ritonavir-boosted protease inhibitor. Raltegravir, emtricitabine may useful PEP.